Outcomes of rituximab therapy in refractory lupus: A meta-analysis.

Fatma Alshaiki Elaf Obaid Abdulqader Almuallim Rabab Taha Hadeel El-Haddad Hani M Almoallim

Published in: European journal of rheumatology (2018)

RTX therapy in refractory SLE and LN patients proved clinical efficacy and favorable safety outcomes. Larger well-designed randomized clinical trials are warranted.

Keyphrases

systemic lupus erythematosus
end stage renal disease
newly diagnosed
ejection fraction
disease activity
prognostic factors
diffuse large b cell lymphoma
type diabetes
rheumatoid arthritis
patient reported outcomes
mesenchymal stem cells
bone marrow
cell therapy
hodgkin lymphoma
glycemic control
patient reported